Facing the looming threat of AMR, researchers finally have a new clue as to why attempts to develop an effective S. aureus vaccine have failed. BioSpace spoke with the team leaders.

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and bioMérieux, a world leader in in vitro diagnostics, have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).

COVID-19 vaccine acceptance increased 3.7% between 2020 and 2021, according to a new study from researchers at the CUNY Graduate School of Public Health and Health Policy (CUNY SPH), the Barcelona Institute for Global Health (ISGlobal), the Dalhousie University and the University of Calgary.

When GSK’s consumer health spinoff Haleon launches later this month, the new business will carry more than $12 billion in debt when it lists on the London Stock Exchange.

The quest to develop a new treatment approach to amyotrophic lateral sclerosis (ALS) may soon be shortened due to the discovery of new potential therapeutic targets by Insilico Medicine.

Lysogene's Phase II/III trial assessing LYS-SAF302 for the treatment of MPS IIIA, also known as Sanfilippo syndrome type A, revealed positive biomarker data, spurring hope for a potential treatment.

BioSpace caught up with Roland and Ben Buelow of Ancora, and Lightspeed Venture Partners' Galym Imanbayev to talk about the AstraZeneca deal and the company's unique business model.

DiaMedica Therapeutics’ Phase II/III ReMEDy2 trial is on hold by the FDA because patients were experiencing severe drops in blood pressure.

Portage Biotech announced Wednesday that it has inked an acquisition agreement with New York-based Tarus Therapeutics, adding four new candidates to its pipeline.

Emory University's Ken Thorpe told BioSpace that the average Medicaid spending on drugs approved under the accelerated pathway in relation to total Medicaid spending is.2%.

The granting of the EUA comes with certain limitations, as the prescribing pharmacist must refer patients for clinical assessment with a physician.

A Senate Finance Committee report shows the majority of AbbVie's income is taxed through foreign subsidiaries, allowing the company to pay less than half the U.S. corporate tax rate.

Intercept Pharmaceuticals, Annovis Bio and Biohaven Pharma are moving forward with late-stage Phase III clinical trials.

Researchers from Osaka University have released details on how they discovered a unique, albeit strange, potential treatment method for cancer - parasitic worms.

Mogrify and Astellas have forged a collaboration surrounding in vivo regenerative medicine approaches, while CardiNor inked a distribution deal with IBL-America.

BioSpace sat down with Axogen's Chief Human Resources Officer Maria Martinez to understand why now is the best time to make the switch to pharma and biotech.

As the global life sciences industry slows down, companies are gathering money through means other than VC funding. BioSpace shines a light on some of these recent transactions.

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) and granted Priority Review for Lunsumio® (mosunetuzumab), a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies.

Sarepta Therapeutics and its partner, Roche, presented promising functional data from several trials of its gene therapy for Duchenne muscular dystrophy.

​​​​​​​CureVac has filed a lawsuit against BioNTech and two of its subsidiaries for allegedly infringing on its intellectual property rights over mRNA technology used in the COVID-19 vaccine.